Counseling the patient with sickle cell disease about reproduction: Pregnancy outcome does not justify the maternal risk!

Fort, Arthur T.; Morrison, John C.; Berreras, Luis; Diggs, L. W.; Fish, Stewart A.

doi:10.1016/0002-9378(71)90772-1

Cited by 74 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pregnancy in women with SCD is currently viewed more favorably 4 than it was during the 1970s, when its avoidance was recommended. 5 Nevertheless, maternal and fetal morbidity and mortality [6][7][8][9] are still encountered, and further examination of interventions capable of mitigating these adverse pregnancy outcomes is needed.…”

Section: Introductionmentioning

confidence: 99%

Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis

Malinowski

Shehata

D’Souza

et al. 2015

Blood

View full text Add to dashboard Cite

Key Points• Prophylactic transfusion in pregnant women with SCD may reduce maternal mortality, vaso-occlusive pain events, and pulmonary complications.• Prophylactic transfusion in pregnant women with SCD may similarly reduce perinatal mortality, neonatal death, and preterm birth.Pregnancy in women with sickle cell disease is associated with adverse maternal and neonatal outcomes. Studies assessing the effects of prophylactic red blood cell transfusions on these outcomes have drawn inconsistent conclusions. The objective of this systematic review was to assess the effect of prophylactic compared with on-demand red blood cell transfusions on maternal and neonatal outcomes in women with sickle cell disease. A systematic search of several medical literature databases was conducted. Twelve studies involving 1291 participants met inclusion criteria. , and preterm birth (9 studies, 1123 participants; OR, 0.59; 95% CI, 0.37-0.96). Event rates for most of the results were low. Prophylactic transfusions may positively impact several adverse maternal and neonatal outcomes in women with sickle cell disease; however, the evidence stems from a relatively small number of studies with methodologic limitations. A prospective, multicenter, randomized trial is needed to determine whether the potential benefits balance the risks of prophylactic transfusions. (Blood. 2015;126(21):2424-2435

show abstract

Section: Introductionmentioning

confidence: 99%

Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis

Malinowski

Shehata

D’Souza

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…Prior to 1972, women with SCD experienced such high rates of maternal and perinatal mortality that providers recommended SCD patients avoid or electively terminate pregnancy. 14,15 Although there have been many medical advancements to reduce mortality, pregnancy in this population is still defined by a higher rate of complications, including preterm labor, premature rupture of membranes, postpartum infection, intrauterine growth restriction, low birth weight, and preterm delivery. 16 Women with SCD are also more likely to experience DVT/PE, which has contributed to a significant number of maternal deaths in this population.…”

Section: Improve Understanding Of Maternal and Infant Outcomesmentioning

confidence: 99%

Developing a Public Health Research Agenda for Women with Blood Disorders

Byams

Beckman

Grant

et al. 2010

Journal of Women's Health

View full text Add to dashboard Cite

Bleeding and clotting in women is an issue that directly affects the life of every woman, child, and family worldwide. This article summarizes recent activities undertaken by the Division of Blood Disorders (DBD) at the Centers for Disease Control and Prevention (CDC) to identify risk factors through evidence-based research and surveillance to prevent complications of blood disorders in women. Specific focus is given to our efforts to improve early identification and diagnosis of blood disorders among women, improve our understanding of maternal and infant outcomes, and develop surveillance systems to monitor the prevalence and incidence of these events.

show abstract

“…The high maternal and fetal morbidity of early reports (Fort et al, 1971;Pritchard et al, 1973) appeared to justify the use of prophylactic transfusions, which, although not in a controlled study, was associated with a better outcome when compared to historic controls (Ricks, 1968). However, many other aspects of management in pregnancy also improved over that period, confounding conclusions based on historic controls.…”

mentioning

confidence: 89%

Chronic Transfusion Programmes in Sickle Cell Disease: Problem or Panacea?

Serjeant

1997

Br J Haematol

View full text Add to dashboard Cite

Counseling the patient with sickle cell disease about reproduction: Pregnancy outcome does not justify the maternal risk!

Cited by 74 publications

References 4 publications

Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis

Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis

Developing a Public Health Research Agenda for Women with Blood Disorders

Chronic Transfusion Programmes in Sickle Cell Disease: Problem or Panacea?

Contact Info

Product

Resources

About